1. any physical examination results, laboratory abnormalities and/or any medical history of the subject may, in the investigator's judgment, endanger the subject's safety by participating in the study; 2. use of an anti-coronavirus treatment such as paxlovid (nematavir/ritonavir combination package) within 3 half-lives before the first dose or during the study period, about 6.05 h at t1/2), azvudine tablets (about 9 h at t1/2), and monolavir capsules (about 3.3 h at t1/2) h), ambavirumab/romisivir injection (t1/2 about 45 days /75 days), covid-19 human immunoglobulin (t1/2 about 3-4 weeks) or recovery plasma (t1/2 about 21 days), deuremidvir hydrobromide tablets (t1/2 about 4.80-6.95 hours), senotevir tablets/ritonavir tablets the combination package (t1/2 about 4.14 h), baritinib (t1/2 about 12.5 h), tocilizumab (t1/2 about 21.5 days), remdesivir (t1/2 about 27 h), lenreterivir (t1/2 about 14.9 h), favelavir (t1/2 about 4.5 h) h), 2-deoxy-d-glucose (t1/2 about 50 min), etc. 3. critically ill patients with clinically confirmed 2019-ncov infection according to the diagnosis and treatment protocol for 2019 novel coronavirus infection (trial version 10) issued by the national health commission of the people's republic of china; 4. stage 4 severe chronic kidney disease requiring dialysis (i.e., estimated glomerular filtration rate \[egfr\] \< 30 ml/min/1.73 m2), an increase in serum creatinine of 44.2 μmol/l within 7 days, oliguria (\< 400 ml/24 hours) or anuria (\< 100 ml/24 hours); 5. during pregnancy or lactation; 6. they will be transferred to another hospital other than the study site within 72 hours; 7. known to be allergic to the test drug and its components; 8. no live vaccine (live attenuated vaccine) was administered within 2 weeks before randomization or during study treatment and safety follow-up; 9. subjects participating in another clinical study at the same time. a washout period of 5 half-lives is required (depending on the study drug or 30 days from any previous study, whichever is longer); 10. total bilirubin (tbl) \> 2× upper limit of normal (uln), alanine aminotransferase (alt) \> 5×uln, aspartate aminotransferase (ast) \> 5×uln, or alkaline phosphatase \> 5×uln; 11. platelet count \< 50×109/l or hemoglobin \< 70 g/l; 12. other factors that the investigator deemed inappropriate for trial entry. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.

1. any physical examination results, laboratory abnormalities and/or any medical history of the subject may, in the investigator's judgment, endanger the subject's safety by participating in the study; 2. use of an anti-coronavirus treatment such as paxlovid (nematavir/ritonavir combination package) within 3 half-lives before the first dose or during the study period, about 6.05 h at t1/2), azvudine tablets (about 9 h at t1/2), and monolavir capsules (about 3.3 h at t1/2) h), ambavirumab/romisivir injection (t1/2 about 45 days /75 days), covid-19 human immunoglobulin (t1/2 about 3-4 weeks) or recovery plasma (t1/2 about 21 days), deuremidvir hydrobromide tablets (t1/2 about 4.80-6.95 hours), senotevir tablets/ritonavir tablets the combination package (t1/2 about 4.14 h), baritinib (t1/2 about 12.5 h), tocilizumab (t1/2 about 21.5 days), remdesivir (t1/2 about 27 h), lenreterivir (t1/2 about 14.9 h), favelavir (t1/2 about 4.5 h) h), 2-deoxy-d-glucose (t1/2 about 50 min), etc. 3. critically ill patients with clinically confirmed 2019-ncov infection according to the diagnosis and treatment protocol for 2019 novel coronavirus infection (trial version 10) issued by the national health commission of the people's republic of china; 4. stage 4 severe chronic kidney disease requiring dialysis (i.e., estimated glomerular filtration rate \[egfr\] \< 30 ml/min/1.73 m2), an increase in serum creatinine of 44.2 μmol/l within 7 days, oliguria (\< 400 ml/24 hours) or anuria (\< 100 ml/24 hours); 5. during pregnancy or lactation; 6. they will be transferred to another hospital other than the study site within 72 hours; 7. known to be allergic to the test drug and its components; 8. no live vaccine (live attenuated vaccine) was administered within 2 weeks before randomization or during study treatment and safety follow-up; 9. subjects participating in another clinical study at the same time. a washout period of 5 half-lives is required (depending on the study drug or 30 days from any previous study, whichever is longer); 10. total bilirubin (tbl) \> 2× upper limit of normal (uln), alanine aminotransferase (alt) \> 5×uln, aspartate aminotransferase (ast) \> 5×uln, or alkaline phosphatase \> 5×uln; 11. platelet count \< 50×109/l or hemoglobin \< 70 g/l; 12. other factors that the investigator deemed inappropriate for trial entry. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.

any physical examination results, laboratory abnormalities and/or any medical history of the subject may, in the investigator's judgment, endanger the subject's safety by participating in the study; use of an anti-coronavirus treatment such as paxlovid (nematavir/ritonavir combination package) within 3 half-lives before the first dose or during the study period, about 6.05 h at t1/2), azvudine tablets (about 9 h at t1/2), and monolavir capsules (about 3.3 h at t1/2) h), ambavirumab/romisivir injection (t1/2 about 45 days /75 days), covid-19 human immunoglobulin (t1/2 about 3-4 weeks) or recovery plasma (t1/2 about 21 days), deuremidvir hydrobromide tablets (t1/2 about 4.80-6.95 hours), senotevir tablets/ritonavir tablets the combination package (t1/2 about 4.14 h), baritinib (t1/2 about 12.5 h), tocilizumab (t1/2 about 21.5 days), remdesivir (t1/2 about 27 h), lenreterivir (t1/2 about 14.9 h), favelavir (t1/2 about 4.5 h) h), 2-deoxy-d-glucose (t1/2 about 50 min), etc. critically ill patients with clinically confirmed 2019-ncov infection according to the diagnosis and treatment protocol for 2019 novel coronavirus infection (trial version 10) issued by the national health commission of the people's republic of china; stage 4 severe chronic kidney disease requiring dialysis (i.e., estimated glomerular filtration rate [egfr] < 30 ml/min/1.73 m2), an increase in serum creatinine of 44.2 μmol/l within 7 days, oliguria (< 400 ml/24 hours) or anuria (< 100 ml/24 hours); during pregnancy or lactation; they will be transferred to another hospital other than the study site within 72 hours; known to be allergic to the test drug and its components; no live vaccine (live attenuated vaccine) was administered within 2 weeks before randomization or during study treatment and safety follow-up; subjects participating in another clinical study at the same time. a washout period of 5 half-lives is required (depending on the study drug or 30 days from any previous study, whichever is longer); total bilirubin (tbl) > 2× upper limit of normal (uln), alanine aminotransferase (alt) > 5×uln, aspartate aminotransferase (ast) > 5×uln, or alkaline phosphatase > 5×uln; platelet count < 50×109/l or hemoglobin < 70 g/l; other factors that the investigator deemed inappropriate for trial entry. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.

any physical examination results, laboratory abnormalities and/or any medical history of the subject may, in the investigator's judgment, endanger the subject's safety by participating in the study; use of an anti-coronavirus treatment such as paxlovid (nematavir/ritonavir combination package) within 3 half-lives before the first dose or during the study period, about 6.05 h at t1/2), azvudine tablets (about 9 h at t1/2), and monolavir capsules (about 3.3 h at t1/2) h), ambavirumab/romisivir injection (t1/2 about 45 days /75 days), covid-19 human immunoglobulin (t1/2 about 3-4 weeks) or recovery plasma (t1/2 about 21 days), deuremidvir hydrobromide tablets (t1/2 about 4.80-6.95 hours), senotevir tablets/ritonavir tablets the combination package (t1/2 about 4.14 h), baritinib (t1/2 about 12.5 h), tocilizumab (t1/2 about 21.5 days), remdesivir (t1/2 about 27 h), lenreterivir (t1/2 about 14.9 h), favelavir (t1/2 about 4.5 h) h), 2-deoxy-d-glucose (t1/2 about 50 min), etc. critically ill patients with clinically confirmed 2019-ncov infection according to the diagnosis and treatment protocol for 2019 novel coronavirus infection (trial version 10) issued by the national health commission of the people's republic of china; stage 4 severe chronic kidney disease requiring dialysis (i.e., estimated glomerular filtration rate [egfr] < 30 ml/min/1.73 m2), an increase in serum creatinine of 44.2 μmol/l within 7 days, oliguria (< 400 ml/24 hours) or anuria (< 100 ml/24 hours); during pregnancy or lactation; they will be transferred to another hospital other than the study site within 72 hours; known to be allergic to the test drug and its components; no live vaccine (live attenuated vaccine) was administered within 2 weeks before randomization or during study treatment and safety follow-up; subjects participating in another clinical study at the same time. a washout period of 5 half-lives is required (depending on the study drug or 30 days from any previous study, whichever is longer); total bilirubin (tbl) > 2× upper limit of normal (uln), alanine aminotransferase (alt) > 5×uln, aspartate aminotransferase (ast) > 5×uln, or alkaline phosphatase > 5×uln; platelet count < 50×109/l or hemoglobin < 70 g/l; other factors that the investigator deemed inappropriate for trial entry. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.

in the investigator's judgment, the subject has any physical examination results, laboratory abnormalities, and/or any history of disease that would endanger his safety by participating in the study; comply with national weijianwei "new coronavirus infection pneumonia diagnosis and treatment plan 9 (trial version)" clinical diagnosis of type new coronavirus pneumonia in critically ill patients; line 4 severe chronic kidney disease, or need dialysis (that is, the estimated glomerular filtration rate (egfr) < 30 ml/min / 1.73 m2), or within 7 days of the serum creatinine increased 44.2 mu mol/l, or oliguria (< 400 ml / 24 hours) or no urine (< 100 ml / 24 hours); during pregnancy or lactation; will be moved to within 72 hours is not the another hospital research center; research on any drug allergies; used as anticancer drugs, graft rejection drugs or immune regulating biological agents (group into the first 30 days or five half-life [will be subject to a long time]); long-term use of corticosteroids and oral > 10 mg prednisone, a day for 3 months or more (allow oral every other day 10 mg prednisone); randomization or research within 2 weeks before treatment and safety shall not be used during the follow-up period live vaccine (live attenuated); at the same time to participate in another clinical research subjects. a washout period of 5 half-lives (depending on the drug under study or 30 days from any previous study, whichever is longer) is required; total bilirubin (tbl) > 2 x normal limit (uln), and alanine aminotransferase (alt) > 5 x uln, or aspartate amino transferase (ast) > 5 x uln, or alkaline phosphatase (> 5 x uln; platelet < 50 * 109 / l, or hemoglobin < 70 g/l; researchers say other factors not appropriate in this test. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.

in the investigator's judgment, the subject has any physical examination results, laboratory abnormalities, and/or any history of disease that would endanger his safety by participating in the study; comply with national weijianwei "new coronavirus infection pneumonia diagnosis and treatment plan 9 (trial version)" clinical diagnosis of type new coronavirus pneumonia in critically ill patients; line 4 severe chronic kidney disease, or need dialysis (that is, the estimated glomerular filtration rate (egfr) < 30 ml/min / 1.73 m2), or within 7 days of the serum creatinine increased 44.2 mu mol/l, or oliguria (< 400 ml / 24 hours) or no urine (< 100 ml / 24 hours); during pregnancy or lactation; will be moved to within 72 hours is not the another hospital research center; research on any drug allergies; used as anticancer drugs, graft rejection drugs or immune regulating biological agents (group into the first 30 days or five half-life [will be subject to a long time]); long-term use of corticosteroids and oral > 10 mg prednisone, a day for 3 months or more (allow oral every other day 10 mg prednisone); randomization or research within 2 weeks before treatment and safety shall not be used during the follow-up period live vaccine (live attenuated); at the same time to participate in another clinical research subjects. a washout period of 5 half-lives (depending on the drug under study or 30 days from any previous study, whichever is longer) is required; total bilirubin (tbl) > 2 x normal limit (uln), and alanine aminotransferase (alt) > 5 x uln, or aspartate amino transferase (ast) > 5 x uln, or alkaline phosphatase (> 5 x uln; platelet < 50 * 109 / l, or hemoglobin < 70 g/l; researchers say other factors not appropriate in this test. note: researchers should ensure that participants when screening meets all inclusion/exclusion standard. if a subject's status changes (including laboratory results) between screening and initial dosing and if the subject meets one of the exclusion criteria, the subject shall be excluded from the study.